Literature DB >> 26838739

Biliverdin protects against cisplatin-induced apoptosis of renal tubular epithelial cells.

Qian Lv1, Ying Yao2, Wei Wang3, Wei Xiong1, Wen-Hui Liao4.   

Abstract

Biliverdin (BV) has long been thought to be a cytotoxic metabolic waste product. It has also been demonstrated to have important cytoprotective functions during oxidative stress. The present study aimed to examine the cytoprotective effect of BV on NRK-52E cells, a proximal tubular cell line derived from rat kidney. Cells were treated with 50 µmol/L cisplatin for 24 h (cisplatin group) or pre-treated with BV for 30 min, then with 50 µmol/L cisplatin for 24 h (cisplatin+BV group). Those given no treatment served as a control. Cell apoptosis was evaluated by flow cytometry and cell viability by Cell Counting Kit-8 (CCK-8). The protein expressions of cleaved caspase3, Bax and Bcl-2 were assessed by Western blotting. Reactive oxygen species (ROS) levels were measured using carboxydichlorodihydrofluorescein diacetate (H2DCF). The results showed that cisplatin induced the apoptosis of NRK-52E cells, decreased cell viability, and increased the formation of ROS by upregulating the expression of cleaved caspase3 and Bax and decreasing Bcl-2 protein expression. These effects could be significantly reversed by pretreatment with BV. It was concluded that BV can protect against cisplatin-induced cell apoptosis through the anti-oxidative effects.

Entities:  

Keywords:  apoptosis; biliverdin; cisplatin; reactive oxygen species

Mesh:

Substances:

Year:  2016        PMID: 26838739     DOI: 10.1007/s11596-016-1540-8

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  25 in total

Review 1.  Bilirubin benefits: cellular protection by a biliverdin reductase antioxidant cycle.

Authors:  Thomas W Sedlak; Solomon H Snyder
Journal:  Pediatrics       Date:  2004-06       Impact factor: 7.124

2.  Human biliverdin reductase is an ERK activator; hBVR is an ERK nuclear transporter and is required for MAPK signaling.

Authors:  Nicole Lerner-Marmarosh; Tihomir Miralem; Peter E M Gibbs; Mahin D Maines
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-07       Impact factor: 11.205

3.  Short- and long-term survival after acute kidney injury.

Authors:  Sean M Bagshaw
Journal:  Nephrol Dial Transplant       Date:  2008-07       Impact factor: 5.992

Review 4.  Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update.

Authors:  Neife Aparecida Guinaim dos Santos; Maria Augusta Carvalho Rodrigues; Nadia Maria Martins; Antonio Cardozo dos Santos
Journal:  Arch Toxicol       Date:  2012-03-01       Impact factor: 5.153

5.  Cilastatin attenuates cisplatin-induced proximal tubular cell damage.

Authors:  Sonia Camano; Alberto Lazaro; Estefania Moreno-Gordaliza; Ana M Torres; Carmen de Lucas; Blanca Humanes; Jose A Lazaro; M Milagros Gomez-Gomez; Lisardo Bosca; Alberto Tejedor
Journal:  J Pharmacol Exp Ther       Date:  2010-04-30       Impact factor: 4.030

6.  Acute kidney injury, mortality, length of stay, and costs in hospitalized patients.

Authors:  Glenn M Chertow; Elisabeth Burdick; Melissa Honour; Joseph V Bonventre; David W Bates
Journal:  J Am Soc Nephrol       Date:  2005-09-21       Impact factor: 10.121

7.  Biliverdin reductase: a major physiologic cytoprotectant.

Authors:  David E Baranano; Mahil Rao; Christopher D Ferris; Solomon H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-27       Impact factor: 11.205

8.  Cellular and molecular studies on cisplatin-induced apoptotic cell death in rat kidney.

Authors:  David Sheikh-Hamad; William Cacini; Arthur R Buckley; Jorge Isaac; Luan D Truong; Chun Chui Tsao; Bellamkonda K Kishore
Journal:  Arch Toxicol       Date:  2003-10-10       Impact factor: 5.153

Review 9.  Cisplatin nephrotoxicity: mechanisms and renoprotective strategies.

Authors:  N Pabla; Z Dong
Journal:  Kidney Int       Date:  2008-02-13       Impact factor: 10.612

Review 10.  Cisplatin and platinum drugs at the molecular level. (Review).

Authors:  Teni Boulikas; Maria Vougiouka
Journal:  Oncol Rep       Date:  2003 Nov-Dec       Impact factor: 3.906

View more
  3 in total

1.  Danshen modulates Nrf2-mediated signaling pathway in cisplatin-induced renal injury.

Authors:  Si-Si Cao; Miao Yan; Zhen-Yan Hou; Ying Chen; Yun-Sheng Jiang; Xin-Rong Fan; Ping-Fei Fang; Bi-Kui Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-10-20

2.  Biliverdin Protects Against Cerebral Ischemia/Reperfusion Injury by Regulating the miR-27a-3p/Rgs1 Axis.

Authors:  Junjie Li; Lijia Peng; Wenya Bai; Peihua Peng; Wendong Chen; Wei Yang; Jianlin Shao
Journal:  Neuropsychiatr Dis Treat       Date:  2021-04-22       Impact factor: 2.570

3.  Induction of cell apoptosis by biliverdin reductase inhibitor in MCF-7 and MDA-MB-468 breast cancer cell lines: Experimental and in silico studies.

Authors:  Seyedeh Zahra Shahrokhi; Fatemeh Soghra Karami Tehrani; Siamak Salami
Journal:  EXCLI J       Date:  2021-10-21       Impact factor: 4.068

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.